This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
Is Alexion Pharmaceuticals (ALXN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ALXN) Outperforming Other Medical Stocks This Year?
Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) encourages with better-than-expected earnings and revenues in Q3
Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) betters loss estimates in Q3. However, its only marketed drug, Nerlynx, disappoints with low sequential growth and as a result, shares take a hit.
Biotech ETFs in Focus on String of Q3 Earnings Beat
by Zacks Equity Research
Biotech ETFs draw attention post impressive Q3 results.
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal
by Zacks Equity Research
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Alexion Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Alexion Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Alexion's (ALXN) Earnings Beat Estimates in Q3, Guidance Up
by Zacks Equity Research
Alexion (ALXN) beats earnings estimates and marginally misses sales estimates in the third quarter of 2018. The company also inks a deal to acquire Syntimmune for $1.2 billion.
Alexion Pharmaceuticals (ALXN) Tops Q3 Earnings Estimates
by Zacks Equity Research
Alexion (ALXN) delivered earnings and revenue surprises of 15.43% and -0.19%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT
by Zacks Equity Research
Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.
Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Let's look at the factors that will impact Alexion's (ALXN) third -quarter 2018 earnings scheduled to release on Oct 24.
Alexion Pharmaceuticals (ALXN) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
by Zacks Equity Research
The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.
5 Top Healthcare Mutual Funds to Buy in October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make healthcare funds a strong investment option
5 Best Biotech Stocks to Buy In October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October
Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion
by Zacks Equity Research
Alexion (ALXN) will acquire clinical-stage biotech company, Syntimmune for $1.2 billion to augment its rare disease pipeline.
Company News For Sep 27, 2018
by Zacks Equity Research
Companies in the news are: WOR, ALXN, NKE and PZZA
Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars
by Zacks Equity Research
Data read-outs by quite a few companies grabbed headlines in the biotech sector this week.
Alexion's Soliris Successful in Phase III Study for NMOSD
by Zacks Equity Research
Alexion's (ALXN) efforts to expand lead blockbuster drug Soliris' label gets a boost as the phase III study on the drug for the indication of NMSOD was successful.
Alexion Pharmaceuticals (ALXN) Surges: Stock Moves 5.3% Higher
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco
by Zacks Equity Research
The biotech sector witnesses a pretty low key week with a handful of regulatory updates. Regeneron secures an FDA approval for the label expansion of its key drug Eylea.
Alexion's BLA for ALXN1210 Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Top Analyst Reports: Mastercard, AbbVie, Twenty-First Century Fox & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks, including Mastercard (MA), AbbVie (ABBV) and Twenty-First Century Fox (FOXA).
Biotech ETFs in Focus on String of Q2 Earnings Beat
by Sanghamitra Saha
Biotech ETFs draw attention post impressive Q2 results.
ALXN vs. RGNX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. RGNX: Which Stock Is the Better Value Option?